Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Copper near 7-year high on Biden transition, vaccine hopes, low China stocks

11/24/2020 | 09:40pm EST

Nov 25 (Reuters) - London copper climbed on Wednesday to its highest in nearly seven years, as U.S. political stability, COVID-19 vaccine developments and China demand boosted investor confidence.

U.S. President-elect Joe Biden beginning his transition to the White House ends weeks of post-election political uncertainty in the world's biggest economy, while his $2 trillion climate plan would see rising demand for copper.

Three-month copper on the London Metal Exchange rose as much as 0.9% to $7,360 a tonne, a level unseen since January 2014.

The most-traded January copper contract on the Shanghai Futures Exchange hit a 33-month high at 55,100 yuan ($8,372.08) a tonne.

Boosting investor sentiment were also developments on the coronavirus vaccine front and low copper inventories in China, the world's biggest consumer of the metal.

Copper stocks in ShFE warehouses <CU-STX-SGH> were at their lowest since December 2014 at 96,766 tonnes, while premiums for imported copper into the country <CU-BMPBW-SHMET> were at a one-month high of $53 a tonne, indicating improving demand.

AstraZeneca, Pfizer-BioNTech, and Moderna have all reported positive results in their coronavirus vaccine trials.


* The global zinc market surplus in September rose to 33,100 tonnes from 31,500 tonnes in August, data from the International Lead and Zinc Study Group showed.

* For the top stories in metals and other news, click or


* Asian stocks made early gains, following a world rally overnight that saw the Dow Jones benchmark crack 30,000 for the first time as investors cheered a dramatically improved global outlook.


1330 US Durable Goods Oct

1330 US GDP 2nd Estimate Q3

1330 US Initial Jobless Clm Weekly

1500 US Consumption Adjusted MM Oct

1500 US U Mich Sentiment Final Nov

1500 US New Home Sales-Units Oct

1900 US Federal Open Market Committee will release

minutes from its November 4-5 policy meeting

($1 = 6.5814 yuan) (Reporting by Mai Nguyen; Editing by Subhranshu Sahu)

© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -2.18% 7779 Delayed Quote.8.57%
BIONTECH SE -0.30% 105.97 Delayed Quote.30.39%
PFIZER INC. -2.87% 36.24 Delayed Quote.1.36%
UNITED STATES DOLLAR (B) / CHINESE YUAN IN HONG KONG (USD/CNH) 0.33% 6.4933 Delayed Quote.-0.15%
All news about ASTRAZENECA PLC
10:52pPFIZER : Tensions rise as AstraZeneca, EU spar over vaccine delays
10:44pGLANCY PRONGAY & MURRAY LLP : a Leading Securities Fraud Law Firm, Announces Inv..
09:07pASTRAZENECA : Morocco to start vaccinations on Thursday, palace says
08:58pEU Clashes With AstraZeneca Over Covid-19 Vaccine Shortfall
08:36pEU health official blasts slow vaccine delivery, and is consulting with Canad..
08:29pDo we need to sanction each other? German minister asks after Blinken call
07:48pRussia warns of delays in Sputnik V vaccine supply to Latin America
06:29pASTRAZENECA : Battling COVID-19, South Africa prepares for first vaccines
05:54pOxford scientists expect some vaccine data on UK mutant virus by next week
05:43pSHAREHOLDER ACTION ALERT : The Schall Law Firm Announces the Filing of a Class A..
More news
Financials (USD)
Sales 2020 26 378 M - -
Net income 2020 2 951 M - -
Net Debt 2020 13 468 M - -
P/E ratio 2020 43,7x
Yield 2020 2,58%
Capitalization 140 B 140 B -
EV / Sales 2020 5,83x
EV / Sales 2021 5,00x
Nbr of Employees 70 600
Free-Float 95,7%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 25
Average target price 127,03 $
Last Close Price 109,27 $
Spread / Highest target 43,8%
Spread / Average Target 16,3%
Spread / Lowest Target -17,4%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON8.32%448 796
ROCHE HOLDING AG4.51%312 213
NOVARTIS AG0.81%214 457
PFIZER INC.1.36%207 384
MERCK & CO., INC.-1.89%203 035